Real-world effectiveness and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes and renal impairment: a subgroup analysis of the ATOS study

被引：0
|
作者：
Tirosh, A. [1 ,2 ]
Khan, N. [3 ]
Vargas-Uricoechea, H.
Mabunay, M. A. N. [4 ]
Coudert, M. [5 ]
Pilorget, V. [5 ]
Galstyan, G. [6 ]
机构：
[1] Chaim Sheba Med Ctr, Div Endocrinol Diabet & Metab, Tel Hashomer, Israel
[2] Tel Aviv Univ, Tel Hashomer, Israel
[3] Imperial Coll London, Diabet Ctr, Al Ain, U Arab Emirates
[4] Univ Cauca, Div Endocrinol & Metab, Dept Internal Med, Popayan Cauca, Colombia
[5] Sanofi, Singapore, Singapore
[6] Hlth Care Minist Russian Federat, Endocrinol Res Ctr, Moscow, Russia
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
506
引用
收藏
页码：264 / 265
页数：2
相关论文
共 50 条
  • [41] Lower hypoglycemia rates with Glargine 300 U/mL vs. insulin Degludec 100 U/mL in insulin-naive adults with type 2 diabetes - The BRIGHT Randomized Study
    Bolli, Geremia
    Scherer, Thomas
    Cheng, Alice
    Bosnyak, Zsolt
    Boelle-Le Corfec, Emmanuelle
    Cali, Anna
    Wang, Xiangling
    Frias, Juan
    Roussel, Ronan
    Rosenstock, Julio
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 369 - 369
  • [42] Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION)
    Al Malki, Faisal
    El Damanhoury, Bandar
    Othman, Abdallah
    Alghamdi, Zain
    AlQahtani, Majed
    Madgy, Amr
    Chouikrat, Zahir
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2869 - 2877
  • [43] New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Ziemen, M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 386 - 394
  • [44] The Impact of Diabetes Duration on Safety and Effectiveness of Insulin Analogs in Insulin-Naive People with Type 2 Diabetes
    Home, Philip
    Khattab, Mohammed
    Swaraj, Soji
    Feriz, Karen
    Prusty, Vinay
    Ghannam, Nadia
    DIABETES, 2014, 63 : A226 - A226
  • [45] Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast during Ramadan: Regional Analysis of the ORION Study
    Hassanein, Mohamed
    Buyukbese, Mehmet A.
    Malek, Rachid, Sr.
    Pilorget, Valerie
    Naqvi, Mubarak
    Berthou, Baptiste
    Shaltout, Inass
    Sahay, Rakesh
    DIABETES, 2020, 69
  • [46] Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Sauriol, Luc
    Aronson, Ronnie
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (07) : 504 - +
  • [47] Improved Glycemic Control with Insulin Glargine 300U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland
    Wiesli, Peter
    Schories, Marcus
    DIABETES THERAPY, 2018, 9 (06) : 2325 - 2334
  • [48] Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Nave Type 2 Diabetes Adults: RESTORE-2 Real-World Study
    Fadini, Gian Paolo
    Buzzetti, Raffaella
    Nicolucci, Antonio
    Rossi, Maria Chiara
    Larosa, Monica
    Cucinotta, Domenico
    DIABETES, 2021, 70
  • [49] Clinical Outcome Assessment of the Effectiveness of Insulin Degludec (Degludec) in Real-life Medical Practice (CONFIRM)-A Comparative Effectiveness Study of Degludec and Insulin Glargine 300U/mL (Glargine U300) in Insulin-Naive Patients with Type 2 Diabetes (T2D)
    Tibaldi, Joseph
    Haldrup, Steffen
    Sandberg, Viktor
    Wolden, Michael L.
    Rodbard, Helena W.
    DIABETES, 2018, 67
  • [50] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
12345